𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment

✍ Scribed by Leslie R. Rowe; Arthur R. Brothman; William E. Nibley; Michael R. Gaffney; Zhong Chen

Book ID
113513073
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
188 KB
Volume
174
Category
Article
ISSN
0165-4608

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Inv (11)(p15q21) in donor-derived Ph-neg
Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation
✍ Bruno C. Medeiros; Kathy Chun; Suzanne Kamel-Reid; Jeffrey Lipton πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 1 views

## Abstract Imatinib mesylate (IM) is the standard first‐line treatment for patients with chronic myeloid leukemia (CML). Surprisingly, 2–15% of patients achieving a complete cytogenetic response develop cytogenetic abnormalities in Philadelphia (Ph)‐negative cells. Following hematopoietic stem cel

Reciprocal Relationship Between a Ph-Neg
Reciprocal Relationship Between a Ph-Negative Clone With Trisomy 8 Associated With Severe Myelodysplasia and a Ph-Positive Clone Following Imatinib Treatment in a Patient With Accelerated-Phase Chronic Myelogenous Leukemia (CML)
✍ Paulina Patchenko; Abraham Klepfish; Luba Trakhtenbrot; Rachel Rothman; Eliezer πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 2 views

## Cytarabine-Induced Neurotoxicity Responding to Methyl Prednisolone To the Editor: Neurotoxicity is a well-recognized complication following high-dose cytosine arabinoside (HIDAC). The pathophysiology of this toxicity is unknown, although an immune-mediated mechanism is hypothesized. We describe